Insider Selling: Biodesix (NASDAQ:BDSX) CEO Sells 3,559 Shares of Stock

February 12, 2026 by InsiderTrades.com

Key Points

CEO Scott Hutton sold 3,559 shares on Feb. 10 at an average price of $10.08 (≈$35,875), reducing his stake by about 7.27% to 45,413 shares valued near $457,763.
Multiple insiders also sold on Feb. 10 (including the CFO and several other executives), a pattern of disposals that could weigh on investor sentiment.
Stock and market context: BDSX opened at $10.35, sits in a 52‑week range of $3.44–$20.40 with 50/200‑day moving averages around $8, a market cap of ≈$82.3M and a negative P/E; short interest recently fell ~48% to ~4.5% of shares, which could be supportive if sustained.

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) CEO Scott Hutton sold 3,559 shares of the business's stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $10.08, for a total value of $35,874.72. Following the completion of the sale, the chief executive officer directly owned 45,413 shares of the company's stock, valued at approximately $457,763.04. This trade represents a 7.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Scott Hutton also recently made the following trade(s):

On Friday, January 16th, Scott Hutton sold 970 shares of Biodesix stock. The stock was sold at an average price of $8.15, for a total value of $7,905.50.

Biodesix Price Performance

Shares of BDSX stock opened at $10.35 on Thursday. Biodesix, Inc. has a fifty-two week low of $3.44 and a fifty-two week high of $20.40. The business's 50 day moving average price is $8.34 and its 200-day moving average price is $7.96. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a market cap of $82.34 million, a P/E ratio of -1.86 and a beta of 0.67.

Trending Headlines about Biodesix

Here are the key news stories impacting Biodesix this week:

Positive Sentiment: Material reduction in short interest at month end (Jan. 30): short interest fell ~48% to 249,443 shares (about 4.5% of shares outstanding), lowering immediate short‑term selling pressure and days‑to‑cover to ~0.6 days. This reduction can be supportive for the stock if sustained.
Neutral Sentiment: February short‑interest reports show anomalous "0 shares" figures for Feb. 10–11 (likely a reporting/data error). These entries are ambiguous and should be treated cautiously until corrected by exchanges or data providers.
Negative Sentiment: CEO Scott Hutton sold 3,559 shares (~$35,875 at ~$10.08), reducing his stake ~7.3% — a potentially negative signal for sentiment because CEO sales often rattle investors. Read More.
Negative Sentiment: CFO Robin Harper Cowie sold 941 shares (~$9,485 at ~$10.08), a ~5.8% reduction in her holding — another executive sale that adds to downward pressure. Read More.
Negative Sentiment: Insider Gary Anthony Pestano sold 540 shares (~$5,443 at ~$10.08), trimming his position ~5.4%. Read More.
Negative Sentiment: Insider Kieran O'Kane sold 584 shares (~$5,887 at ~$10.08), a ~6.2% decrease in his holding. Read More.
Negative Sentiment: CAO Chris Vazquez sold 101 shares (~$1,018 at ~$10.08), trimming ~7.6% of his position — adds to the pattern of multiple insider sales on Feb. 10. Read More.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BDSX shares. Wall Street Zen raised Biodesix from a "sell" rating to a "hold" rating in a research report on Saturday, November 8th. Weiss Ratings restated a "sell (e+)" rating on shares of Biodesix in a research report on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $32.50.

View Our Latest Research Report on BDSX

Hedge Funds Weigh In On Biodesix

A number of large investors have recently bought and sold shares of BDSX. Geode Capital Management LLC grew its position in Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company's stock valued at $289,000 after acquiring an additional 2,235 shares during the last quarter. Monashee Investment Management LLC grew its holdings in shares of Biodesix by 12.3% in the fourth quarter. Monashee Investment Management LLC now owns 112,344 shares of the company's stock worth $764,000 after purchasing an additional 12,348 shares during the last quarter. Millennium Management LLC bought a new stake in Biodesix during the 3rd quarter valued at about $113,000. Oracle Investment Management Inc. purchased a new stake in Biodesix in the 3rd quarter valued at about $113,000. Finally, XTX Topco Ltd grew its stake in Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock worth $58,000 after acquiring an additional 102,494 shares in the last quarter. Hedge funds and other institutional investors own 20.96% of the company's stock.

About Biodesix

(Get Free Report)

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.